Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Japan Should Adopt French-Type HTA: JMA Exec Suzuki
If Japan is to craft a health technology assessment (HTA) scheme by modeling on an overseas example, it should adopt a system similar to one in France, Kunihiko Suzuki, an executive board member of the Japan Medical Association (JMA), said…
To read the full story
Related Article
ORGANIZATION
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
- Five Groups Urge Action to Secure Medical Supplies amid Iran War
April 2, 2026
- JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
April 2, 2026
- UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
April 2, 2026
- JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…